Document Detail

In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
MedLine Citation:
PMID:  8460925     Owner:  NLM     Status:  MEDLINE    
The in vitro activity of FK-037, 5-amino-2-[[(6R, 7R)-7-[[(Z)-2-(2-amino-4-thiazolyl)-2- methoxyimino) acetyl] amino]-2-carboxy-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-(2-hydroxyethyl)-1H-pyrazoli um hydroxide, inner salt, sulfate (1:1), a new parenteral cephem, was compared with those of cefepime, ceftazidime, imipenem, and ciprofloxacin. FK-037 inhibited methicillin-susceptible staphylocci at < or = 4 micrograms/ml. Of 98 isolates of homogenous methicillin-resistant Staphylococcus aureus, 55 (56.1%) were inhibited by 8 micrograms of FK-037 per ml, compared to 3.1% for cefepime. Imipenem was the most active beta-lactam tested against staphylococci. The MIC of FK-037 for 90% of the strains tested (MIC90) was 0.06 micrograms/ml for hemolytic streptococci, Streptococcus pneumoniae, viridans group streptococci, and Streptococcus bovis. The MIC90 for many of the members of the family Enterobacteriaceae was 1 microgram/ml, similar to that of cefepime and lower than those of ceftazidime and imipenem. The MIC90 for Klebsiella pneumoniae and Enterobacter cloacae was 8 micrograms/ml, similar to that for cefepime, but all isolates were inhibited by 2 micrograms of imipenem per ml. K. pneumoniae isolates with cefotaxime and ceftazidime MICs of > 32 micrograms/ml with Bush type 2b' beta-lactamases were inhibited by 4 micrograms of FK-037 per ml. E. cloacae, Citrobacter freundii, and S. aureus stably resistant to FK-037 could be selected by repeated transfer in the presence of FK-037. The FK-037 MIC90 for Pseudomonas aeruginosa was 4 microgram/ml, compared to 32 microgram/ml for cefepime and ceftazidime and 8 microgram/ml for imipenem. Xanthomonas maltophilia, Pseudomonas cepacia, Acinetobacter anitratus, and Bacteroides species were resistant to FK-037 (MIC, more than or equal 32 microgram/ml). MBCs were identical to or within twofold of the MICs except for a 32-fold greater MBC for P. aeruginosa. Inoculum size and acid environment did not lower the activity of FK-037. FK-037 was not appreciably hydrolyzed by Bush group 1, 2a, 2b, and 2e beta-lactamases but was hydrolyzed by 2b' and 2d enzymes at rates comparable to that of ceftazidime. Nonetheless, FK-037 inhibited bacteria possessing TEM-3, -5, and -7 and SHV -5 at less than or equal 8 microgram/ml. Overall, FK-037 has lower MICs against staphylococci and P. aeruginosa than the currently available iminomethoxy aminothiazolyl cephalosporins and has activity against members of the family Enterobacteriaceae comparable to that of cefepime.
H C Neu; N X Chin; H B Huang
Related Documents :
3498005 - Ampicillin resistance and penicillin-binding proteins of haemophilus influenzae.
8508165 - In vitro induced anaerobic resistance to metronidazole in trichomonas vaginalis.
6461705 - Otomycosis: an experimental evaluation of six antimycotic agents.
6233935 - Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and n...
6349685 - A process related to membrane potential involved in bacterial chemotaxis to galactose.
5272345 - Nasal acquisition of staphylococcus aureus in a subdivided and mechanically ventilated ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  37     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  1993 Mar 
Date Detail:
Created Date:  1993-04-28     Completed Date:  1993-04-28     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  566-73     Citation Subset:  IM    
Department of Medicine, College of Physicians & Surgeons, Columbia University, New York 10032, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bacteria / drug effects*,  enzymology
Bacterial Infections / microbiology
Ceftizoxime / administration & dosage,  analogs & derivatives*,  pharmacokinetics,  pharmacology
Citrobacter freundii / drug effects
Enterobacter cloacae / drug effects
Methicillin Resistance
Microbial Sensitivity Tests
Staphylococcus aureus / drug effects
beta-Lactamases / drug effects*,  pharmacokinetics
Reg. No./Substance:
122841-12-7/FK 037; 68401-81-0/Ceftizoxime; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphy...
Next Document:  Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine aga...